Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 5/20 | 0.54 |
| ▸ | CD74 | P04233 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | TSHR | P16473 | 3/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20594828 | 0.86 | MIF (0.53) | MIFCD74MAPTLMNATSHR | |
| SCHEMBL20594721 | 0.78 | POLB (0.56) | MAPTLMNATSHRPOLBTP53 | |
| SCHEMBL14898604 | 0.76 | TP53 (0.53) | MIFCD74MAPTLMNATSHR | |
| SCHEMBL2544422 | 0.76 | MAPT (0.53) | MIFCD74MAPTLMNATSHR | |
| SCHEMBL12241021 | 0.75 | MIF (0.53) | MIFCD74MAPTPOLBTP53 | |
| SCHEMBL14563242 | 0.74 | MAPT (0.62) | MIFCD74MAPTPOLBTP53 | |
| SCHEMBL2546842 | 0.73 | MAPT (0.50) | MIFCD74MAPTLMNATSHR | |
| SCHEMBL10089276 | 0.73 | MIF (0.78) | MIFCD74LMNATSHRL3MBTL1 | |
| SCHEMBL24885166 | 0.73 | ALDH1A1 (0.56) | LMNATSHRPOLBTP53MEN1 | |
| SCHEMBL31119220 | 0.73 | ALDH1A1 (0.56) | LMNATSHRPOLBTP53MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200172483-A1 | HETEROCYCLIC SMALL MOLECULE MODULATORS OF HUMAN STING | CURADEV PHARMA LIMITED (GB) | 2020-06-04 | — | — | US | disclosed |
| US-20200172483-A1 | HETEROCYCLIC SMALL MOLECULE MODULATORS OF HUMAN STING | CURADEV PHARMA LIMITED (GB) | 2020-06-04 | — | — | US | disclosed |
| EP-3642197-A1 | HETEROCYCLIC SMALL MOLECULE MODULATORS OF HUMAN STING | Curadev Pharma Limited (GB) | 2020-04-29 | — | — | EP | disclosed |
| WO-2018234807-A1 | HETEROCYCLIC SMALL MOLECULE MODULATORS OF HUMAN STING | CURADEV PHARMA LIMITED (GB) | 2018-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200172483-A1 | HETEROCYCLIC SMALL MOLECULE MODULATORS OF HUMAN STING | STING1, IRF3, CGAS | MIF 112/4885CD74 129/4885MAPT 4724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.